Rate Video

ASCO 2020 | ZUMA-1: safety and efficacy of axicabtagene in refractory non-Hodgkin lymphoma patients

Sattva Neelapu • 29 May 2020

Follicular Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel

Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the ZUMA-1 study (NCT02348216), investigating the safety and efficacy of axicabtagene ciloleucel, CAR-T cell therapy, in relapsed, aggressive follicular lymphoma and marginal zone lymphoma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Responses to CAR T-Cell therapy still strong after one year in patients with refractory NHL

Axi-cel in older patients: data from ZUMA-1 and clinical use

Sattva Neelapu • 19 Jun 2019

Comparison of ZUMA-1 and SCHOLAR-1 outcomes

Sattva Neelapu • 8 Dec 2019

Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel

Sattva Neelapu • 9 Dec 2017

Related Videos

Future treatment of relapsed iNHL

Matthew Matasar • 12 Apr 2021

CHRONOS-3: copanlisib plus rituximab for relapsed iNHL

Matthew Matasar • 12 Apr 2021

NHL following treatment for classical HL

Dennis Eichenauer • 15 Mar 2021

T-Cell lymphoma: implications of interleukin-10 loss

Ali Bazarbachi • 12 Mar 2021